37 projets européens trouvés
Recherche sur 125080 projets européens
TERMINÉ
Penumbral Rescue by Normobaric O=O Administration in Patients With Ischaemic Stroke and Target Mismatch ProFile: A Phase II Proof-of-Concept Trial (PROOF)
Date du début: 1 janv. 2017, Date de fin: 31 déc. 2021,
Ischemic stroke (IS), caused by occlusion of arteries that supply blood to the brain, remains a leading cause of mortality and morbidity in the world. Disruption of blood and oxygen supply to the brain leads to neuronal death in the ischemic core within minutes. The hypoperfused tissue surrounding the ischemic core, the penumbra, is at high risk for infarction over time but still salvageable. Neur ...
Voir le projet
13
Participants partenaires
TERMINÉ
Combatting Bacterial Resistance in Europe - Molecules against Gram Negative Infections (COMBACTE-MAGNET)
Date du début: 1 janv. 2015, Date de fin: 31 déc. 2021,
Antimicrobial resistance (AMR) is a major global public health threat, and most troublesome is the rapid emergence and dissemination of multidrug resistant (MDR) Enterobacteriaceae, Acinetobacter species and Pseudomonas aeruginosa. There is an unmet medical need to prevent P. aeruginosa infection in critically ill patients and to develop new antibiotics for infections caused by Gram-negative bacte ...
Voir le projet
44
Participants partenaires
TERMINÉ
European HIV Vaccine Alliance (EHVA): a EU platform for the discovery and evaluation of novel prophylactic and therapeutic vaccine candidates (EHVA)
Date du début: 1 janv. 2016, Date de fin: 31 déc. 2020,
...scientists and clinicians; b) the most innovative technologies to profile immune response and virus reservoir; c) the access to large cohort studies bringing together top European clinical scientists/centres in the fields of prophylactic and therapeutic vaccines, d) the access to a panel of experimental HIV vaccines under clinical development that will be used as benchmark, and e) the liaison to a ...
Voir le projet
43
Participants partenaires
TERMINÉ
Professional cross-priming for ovary and prostate cancer (PROCROP)
Date du début: 1 sept. 2015, Date de fin: 31 août 2020,
...rials for two highly prevalent and unsatisfactorily managed malignant conditions. Industrial partnership provides the unique advantage of producing a rigorously standardized product for eventual multicentre trials.
Voir le projet
8
Participants partenaires
TERMINÉ
European Sepsis Academy: towards new biomarkers to improve sepsis management (ESA -ITN)
Date du début: 1 mars 2016, Date de fin: 29 févr. 2020,
ESA-ITN will break through the state of the art in sepsis diagnostics and will train 15 early-stage researchers (ESRs) to determine the clinical potency of a variety of new complementary sepsis biomarkers. These cover the full range of the antiinflammatory response in sepsis, at genetic, molecular and cellular level. Rapid and practical biomarker diagnostics for sepsis will be developed by buildin ...
Voir le projet
7
Participants partenaires
TERMINÉ
DevelopIng Genetic medicines for Severe Combined Immunodeficiency (SCID) (SCIDNET)
Date du début: 1 janv. 2016, Date de fin: 31 déc. 2019,
Severe combined immunodeficiency (SCID) is a devastating rare disorder of immune system development. Affected infants are born without functional immune systems and die within the first year of life unless effective treatment is given. Treatment options are limited to allogeneic haematopoietic stem cell transplantation and autologous stem cell gene therapy. Over the last 15 years, gene therapy for ...
Voir le projet
13
Participants partenaires
TERMINÉ
Combatting Bacterial Resistance in Europe (COMBACTE-NET)
Date du début: 1 janv. 2013, Date de fin: 31 déc. 2019,
The emergence of Antibiotic-resistant bacteria (ARB) is a global problem, having recently been elevated to the top three threats identified by the World Health Organisation (WHO), and subject of numerous national and international government activities, including the Trans-Atlantic Task Force on Antimicrobial Resistance established by the US and EU presidencies. The estimated costs of ARB are aro ...
Voir le projet
38
Participants partenaires
TERMINÉ
Lifecourse biological pathways underlying social differences in healthy ageing (LIFEPATH)
Date du début: 1 mai 2015, Date de fin: 30 avr. 2019,
"The dramatic differentials in healthy ageing, quality of life and life expectancy between individuals of different socioeconomic groups, is a major societal challenge facing Europe. The overarching aim of the LIFEPATH project is to understand the determinants of diverging ageing pathways among individuals belonging to different socio-economic groups. This will be achieved via an original study de ...
Voir le projet
18
Participants partenaires
TERMINÉ
Hyper-emotionality after neurodegenerative loss of inhibition of the amygdala (URBACH-ALZ)
Date du début: 1 janv. 2017, Date de fin: 31 déc. 2018,
"I propose to test how hyper-anxiety in Alzheimer's disease (AD) patients is caused by neurodegeneration in the amygdala, our "center of fear", by comparing with a unique group of Urbach Wiethe disease (UWD) patients with bilateral neurodegeneration of the amygdala (BLA) for which I also construct an animal model. UWD is caused by a very rare genetic mutation occurring in only a handful of individ ...
Voir le projet
1
Participant partenaire
TERMINÉ
TBVAC2020; Advancing novel and promising TB vaccine candidates from discovery to preclinical and early clinical development (TBVAC2020)
Date du début: 1 janv. 2015, Date de fin: 31 déc. 2018,
The TBVAC2020 proposal builds on the highly successful and long-standing collaborations in subsequent EC-FP5-, FP6- and FP7-funded TB vaccine and biomarker projects, but also brings in a large number of new key partners from excellent laboratories from Europe, USA, Asia, Africa and Australia, many of which are global leaders in the TB field. This was initiated by launching an open call for Express ...
Voir le projet
49
Participants partenaires
TERMINÉ
Models of Child Health Appraised (MOCHA)
Date du début: 1 juin 2015, Date de fin: 30 nov. 2018,
Children’s health affects the future of Europe – children are citizens, future workers, parents and carers. Children are dependent on society to provide effective health services (UN Convention on the Rights of the Child). Models of child primary health care vary widely across Europe based on two broad alternatives (primary care paediatricians or generic family doctors), and a variety of models of ...
Voir le projet
20
Participants partenaires
TERMINÉ
Identify novel pathways to enhance the induction of protective CD8+ T cell responses (PROTECTC)
Date du début: 1 oct. 2013, Date de fin: 30 sept. 2018,
There is an urgent need for progress in developing prophylactic and therapeutic vaccination strategies that induce polyfunctional, strongly protective cytotoxic CD8 T cell responses. These could shield us from pathogens against which the presently available, neutralizing antibody-inducing vaccine approaches confer limited or no protection and they could be used to eliminate tumors or chronic infec ...
Voir le projet
2
Participants partenaires
TERMINÉ
Development of Vascular-Disrupting Lymphocyte Therapy for Tumours (Antivessel-T-Cells)
Date du début: 1 août 2013, Date de fin: 31 juil. 2018,
T cell engineering with chimeric antigen receptors has opened the door to effective immunotherapy. CARs are fusion genes encoding receptors whose extracellular domain comprises a single chain variable fragment (scFv) antibody that binds to a tumour surface epitope, while the intracellular domain comprises the signalling module of CD3ζ along with powerful costimulatory domains (e.g. CD28 and/or 4-1 ...
Voir le projet
2
Participants partenaires
TERMINÉ
Human Brain Project Specific Grant Agreement 1 (HBP SGA1)
Date du début: 1 avr. 2016, Date de fin: 31 mars 2018,
Understanding the human brain is one of the greatest scientific challenges of our time. Such an understanding can provide profound insights into our humanity, leading to fundamentally new computing technologies, and transforming the diagnosis and treatment of brain disorders. Modern ICT brings this prospect within reach. The HBP Flagship Initiative (HBP) thus proposes a unique strategy that uses I ...
Voir le projet
126
Participants partenaires
TERMINÉ
Development of a Chimpanzee Adenovirus Type 3 Ebolavirus Zaire Vaccine (EbolaVac)
Date du début: 7 oct. 2014, Date de fin: 6 oct. 2017,
The first Ebolavirus Zaire (EBOV) outbreak of 2014 was declared on 22 March in Guinea. As of 30 September 2014, the World Health Organization (WHO) reports the total number of cases in the current outbreak of Ebola virus disease (EVD) in West Africa at 7470, with 3431 deaths. The US Centers for Disease Control and Prevention states that the number of cases is currently doubling every 20 days and e ...
Voir le projet
5
Participants partenaires
TERMINÉ
Natural sensory feedback for phantom limb pain modulation and therapy (EPIONE)
Date du début: 1 sept. 2013, Date de fin: 31 août 2017,
"Amputation of a limb may result from trauma or surgical intervention. The amputation traumatically alters the body image, but often leaves sensations that refer to the missing body part. In 50-80% amputees, neuropathic pain develops, also called phantom limb pain (PLP). Both peripheral and central nervous system factors have been implicated as determinants of PLP. Also, PLP may be triggered by ph ...
Voir le projet
13
Participants partenaires
TERMINÉ
Development of an innovative paediatric formulation of an antiepileptic agent for the treatment of absence epilepsy in children (KIEKIDS)
Date du début: 1 oct. 2011, Date de fin: 31 mars 2017,
The KIEKIDS project is dedicated to the development of an innovative paediatric formulation of an antiepileptic agent for a safe alternative treatment of absence epilepsy in children.Development of such an age-appropriate formulation is regarded by The European Medicines Agency (EMA) to be amongst one of highest priorities for the treatment of absence seizures, using a drug with identified and doc ...
Voir le projet
4
Participants partenaires
TERMINÉ
Evaluation of phage therapy for the treatment of Escherichia coli and Pseudomonas aeruginosa burn wound infections (Phase I-II clinical trial) (PHAGOBURN)
Date du début: 1 juin 2013, Date de fin: 28 févr. 2017,
Sepsis is the major problem of large burn patients and a predominant cause of death. The burn wound pathology, combined to a global intensive use of antibiotics (ATB), put patients at high risk of suffering from multidrug resistant (MDR) infections, notably carried out by the Gram-negative bacteria species: Pseudomonas aeruginosa or Escherichia coli. But the last Gram- ATB is more than 20 years ol ...
Voir le projet
5
Participants partenaires
TERMINÉ
"From Brain Gene Transfer Towards Gene Therapy: Pharmacological Assessment of AAV, CAV and LVV" (BRAINVECTORS)
Date du début: 1 nov. 2012, Date de fin: 31 oct. 2016,
"BRAINVECTORS aims devising new gene therapy(GT)-based treatments for Parkinson’s and other neurodegenerative diseases, in substitution of current systemic treatments, by delivering neurotrophic factors (GDNF) into the CNS with new vectors derived from adeno-associated (AAV), canine adenoviruses (CAV) and lentiviruses (LV) with inducible gene expression.Although AAV, CAV and LVV are considered acc ...
Voir le projet
12
Participants partenaires
TERMINÉ
Paving the way towards HIV eradication/control (HIT HIDDEN HIV)
Date du début: 1 déc. 2012, Date de fin: 31 oct. 2016,
Major advances in HIV/AIDS treatment regimens have fundamentally altered the natural history of the disease and sharply reduced HIV-related morbidity and mortality in countries where such treatments are accessible. The most notable advance is the use of combination antiretroviral therapy or ART. However, ART is unable to achieve virus eradication or “sterilizing cure”. Indeed, in most cases, viral ...
Voir le projet
5
Participants partenaires
TERMINÉ
EUropean Training and Education for Medical Physics Experts in Radiology (EUTEMPE-RX)
Date du début: 1 août 2013, Date de fin: 31 juil. 2016,
"Medical exposures for radiological examinations represent the highest and fastest growing contribution to manmade radiation exposure in the EU underlying the need for medical physics experts (MPEs), regulators and scientists in industry to bring in new research results and expertise and to deploy resources in addressing this important issue. The EC recognized the urgency and the EU tender ‘Europ ...
Voir le projet
15
Participants partenaires
TERMINÉ
Integrating chemical approaches to treat pancreatic cancer: making new leads for a cure (Panacreas)
Date du début: 1 mars 2011, Date de fin: 29 févr. 2016,
Pancreatic ductal adenocarcinoma (PDAC) causes 34000 deaths in the EU every year. Conventional cancer treatments have close to no impact on this disease. As a result, almost all patients diagnosed with PDAC develop metastases and eventually die. Given this poor outlook, the search for new therapeutics is mandatory. These will have to target relevant cancer pathways and be designed based on the ava ...
Voir le projet
12
Participants partenaires
TERMINÉ
Adopting Hospital Based Health Technology Assessment in EU (AdHopHTA)
Date du début: 1 sept. 2012, Date de fin: 30 nov. 2015,
The use of HTA as a part of the decision-making process at national, regional, and international levels has evolved considerably over the past 35 years. However, still an important number of good-value innovative HTs never reach clinical practice while, in many instances, others with no significant added value actually do. This situation can be effectively overcome by approaching HTA at hospital l ...
Voir le projet
11
Participants partenaires
TERMINÉ
Dissecting the Immunological Interplay between Poverty Related Diseases and Helminth Infections: An African-European Research Initiative (IDEA)
Date du début: 1 mars 2010, Date de fin: 31 août 2015,
...miologists, clinicians, and experts in vaccines, c) cutting edge immunology and the most innovative technologies to profile immune response, d) the access to large cohort studies bringing a number of centres working on worms and PRDs in Africa together, and e) the access to experimental HIV, TB and malaria vaccine candidates under clinical development in Africa.
Voir le projet
23
Participants partenaires
TERMINÉ
Novel multimodal endoscopic probes for simultaneous PET/ultrasound imaging for image-guided interventions (ENDOTOFPET-US)
Date du début: 1 janv. 2011, Date de fin: 30 juin 2015,
In the frame of this project it is proposed to define and build a bi-modal PET-US (Positron Emission Tomography and Ultrasound) endoscopic probe combining in a miniaturized system a fully digital, 200ps time resolution Time of Flight PET detector head (TOF-PET) coupled to a commercial ultrasound (US) assisted biopsy endoscope and to launch the first steps of clinical validation.The project address ...
Voir le projet
16
Participants partenaires
TERMINÉ
Neuroprosthetic interface systems for restoring motor functions (NEUWalk)
Date du début: 1 juin 2010, Date de fin: 30 nov. 2014,
The overall concept of the 48-month Integrated Project NEUWalk is focused specifically on Objective ICT-2009.3.9 Microsystems and Smart Miniaturised Systems with particular emphasis to c) Application-specific microsystems and smart miniaturised systems 1) Biomedical S&T objectives. The technological objective of NEUWalk is to develop novel microtechnology, microelectronics, brain decoding algorith ...
Voir le projet
11
Participants partenaires
TERMINÉ
Systems prediction of Chronic Lung Allograft Dysfunction (SysCLAD)
Date du début: 1 nov. 2012, Date de fin: 31 oct. 2014,
Lung transplantation (LT) is the standard of care for selected patients with chronic respiratory failure. Chronic lung allograft dysfunction (CLAD) (i.e. “Bronchiolitis obliterans syndrome” (BOS) and “Restrictive Allograft Syndrome” (RAS)) represents a major health risk for LT recipients, requiring the use of heavy treatments and possible retransplantation. Observed in almost 50% of patients afte ...
Voir le projet
9
Participants partenaires
TERMINÉ
"Fungi in the setting of inflammation, allergy and autoimmune diseases:Translating basic science into clinical practices" (ALLFUN)
Date du début: 1 déc. 2010, Date de fin: 31 mai 2014,
"The ALLFUN proposal aims at defining the cellular and molecular mechanisms by which ubiquitous airborne or commensal fungi contribute to immune homeostasis and its dysregulation leading to allergy and inflammatory diseases. Breakthroughs in understanding how mucosal homeostasis is established, maintained or disrupted in the presence of fungi should be sources of new therapeutic targets and drugs ...
Voir le projet
14
Participants partenaires
TERMINÉ
Host and viral factors in acute hepatitis C (HEPACUTE)
Date du début: 1 nov. 2010, Date de fin: 30 avr. 2014,
Chronic hepatitis C is one of the most common chronic viral infections of humans and a major cause of chronic liver disease, cirrhosis and liver cancer. Still about 4 million new infections occur world-wide each year with 50-85% of patients progressing to chronic hepatitis C. Currently there is no marker to predict spontaneous viral clearance and to guide treatment decisions.The major objectives o ...
Voir le projet
17
Participants partenaires
TERMINÉ
Prophylactic and therapeutic use of recombinant lymphocytic choriomeningitis virus against melanoma (LCMVACC)
Date du début: 1 avr. 2012, Date de fin: 31 mars 2014,
"Cancer is one of the most common reasons for death of people living in the developed countries. There were an estimated 3.2 million new cases of cancer and 1.7 million deaths in the year 2008 in Europe. Melanoma is a form of skin cancer caused by mutation of melanocytes in the skin. Common cancer therapy is not effective in treatment of metastatic melanoma. The survival rate of patients with this ...
Voir le projet
1
Participant partenaire
TERMINÉ
Optimization of stem cell therapy for clinical trials of degenerative skin and muscle diseases (OptiStem)
Date du début: 1 janv. 2009, Date de fin: 31 déc. 2013,
This proposal aims to develop and implement efficacy of clinical trials with adult, tissue stem cells for degenerative diseases of epithelia and skeletal muscle. Extraordinary progress in the understanding of several key features of stem cells has been rapidly translated into novel cell therapy protocols that have yielded positive results in pre-clinical models of genetic and acquired diseases and ...
Voir le projet
20
Participants partenaires
TERMINÉ
Development of methodology for alternative testing strategies for the assessment of the toxicological profile of nanoparticles used in medical diagnostics (NanoTEST)
Date du début: 1 avr. 2008, Date de fin: 31 mars 2012,
Nanoparticles (NP) have unique, potentially beneficial properties, but their possible impact on human health has not been adequately assessed. The main goal of this proposal is to develop alternative high-throughput testing strategies using in vitro and in silico methods to assess the toxicological profile of NP used in medical diagnostics. Our specific aims are to: 1. Define NP properties and ful ...
Voir le projet
12
Participants partenaires
TERMINÉ
European Network on the Health and Environmental Impact of Nanomaterials (NanoImpactNet)
Date du début: 1 avr. 2008, Date de fin: 31 mars 2012,
Recent technological advances allow the targeted production of objects and materials in the nanoscale (smaller than 100 nm). Nanomaterials have chemical, physical and bioactive characteristics, which are different from those of larger entities of the same materials. Nanoparticles can pass through body barriers. This is interesting for medical applications, but it raises concerns about their health ...
Voir le projet
26
Participants partenaires
TERMINÉ
The interaction of Lassa virus with its cellular receptor alpha-dystroglycan (Lassa virus receptor)
Date du début: 1 mars 2008, Date de fin: 29 févr. 2012,
The arenavirus Lassa fever virus (LFV) causes a severe viral hemorrhagic fever in humans with over 300, 000 infections and thousands of deaths annually. Fatal LFV infection is characterized by marked immunosuppression of the patient, resulting in uncontrolled viral infection with progressive hemorrhagic disease and shock. Since death occurs in absence of a significant anti-viral immune response, t ...
Voir le projet
1
Participant partenaire
TERMINÉ
Optimization of Radiation Protection of Medical Staff (ORAMED)
Date du début: 1 févr. 2008, Date de fin: 31 janv. 2011,
"The state-of-the-art analysis performed in the FP6 CONRAD project highlighted high extremity doses and a lack of systematic data analysis on exposures to the staff in interventional radiology (IR) and nuclear medicine (NM). To optimize the working procedures in the medical field with respect to radiation protection, a project focussed on improving the knowledge on extremity and eye lens exposures ...
Voir le projet
12
Participants partenaires
TERMINÉ
Pathology is a medical specialty that provides the histological (microscopical) diagnoses in clinical settings. Every diagnosis is made by the pathologist himself after microscopic examination of the cells and tissues that are removed from a patient, and this diagnosis is the golden standard for further decisions on treatment and prognosis. At this moment (and in the foreseeable future) there is n ...
Voir le projet
31
Participants partenaires
TERMINÉ
Objectifs : TéNeCi a pour objectif de concevoir une aide a la décision (diagnostic et choix thérapeutique) dans le domaine de la neurologie et de ses urgences. Actions : Le projet repose sur la réalisation de plusieurs étapes successives : 1ere étape : structurer la filiere de diagnostics et améliorer les prises en charge a travers la maitrise technologique de données vidéo par les CHU de Besanco ...
Voir le projet